Positron Emission Tomography (PET) for Alzheimer disease

HAYES, Inc
Record ID 32017000377
English
Authors' recommendations: Positron emission tomography (PET) is a 3-dimensional (3D) nuclear imaging technique that measures the level of physiologic and biochemical activity or other organic function in an organ or tissue by reflecting the distribution of a radiotracer that has been administered to the patient. PET has been proposed as a method for diagnosing and predicting development of Alzheimer disease (AD). Relevant Questions: Is PET an accurate diagnostic test for detection or prediction of the development of AD? How does PET compare with other techniques? What is the impact of PET on clinical management and health outcomes? Are there any safety issues associated with the use of PET for detection or the prediction of AD development? Have definitive patient selection criteria been established for PET imaging for AD?
Details
Project Status: Completed
Year Published: 2017
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: United States
MeSH Terms
  • Alzheimer Disease
  • Fluorodeoxyglucose F18
  • Humans
  • Positron-Emission Tomography
Contact
Organisation Name: HAYES, Inc.
Contact Address: 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name: saleinfo@hayesinc.com
Contact Email: saleinfo@hayesinc.com
Copyright: Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.